XGNExagen, Inc.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and m…
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
Older | ||
 Exagen (XGN) Q2 2026 Earnings Call Transcript Record revenue and near break-even adjusted EBITDA signal progress toward profitability. | ||
 Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution Exagen now carries a modestly higher implied fair value, with the target shifting from about US$8.67 to roughly US$9.71 per share. Analysts link this change to a mix of optimism around the AVISE CTD autoimmune testing portfolio and caution around execution and valuation, as they assess how the current business can support the updated target. Read on to see what this may mean for you as an investor and how to track the evolving Exagen narrative from here. Analyst Price Targets don't always... | ||
 Exagen Inc. Q2 2026 Earnings Call Summary Moby summary of Exagen Inc.'s Q2 2026 earnings call | ||
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability Exagen Inc (XGN) reports record Q2 revenue of $19.9 million, nearly achieving adjusted EBITDA breakeven, and raises full-year guidance. | ||
 Exagen Q2 Earnings Call Highlights Exagen (NASDAQ:XGN) reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even. Revenue for the quarter ended June 30 rose 16% year over year and 15% sequ | ||
 Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance Exagen (NASDAQ:XGN) delivered record quarterly revenue, narrowed losses, improved adjusted EBITDA, and increased its full-year revenue outlook as demand for its autoimmune testing portfolio continued to grow. Key Investor TakeawaysExagen (NASDAQ:XGN) reported record second-quarter revenue of $19. | ||
 Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates Exagen (XGN) delivered earnings and revenue surprises of +31.58% and +10.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||